Related Experiment Video

Updated: Jul 8, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Pentoxifylline ameliorates lithium-pilocarpine induced status epilepticus in young rats

Mohammad Tariq1, Mohammad Ahmad, Khalaf Al Moutaery

  • 1Neuroscience Research Group, Research Center, Riyadh Military Hospital, W-912, PO Box 7897, Riyadh-11159, Saudi Arabia. rkhres@yahoo.com <rkhres@yahoo.com>

Epilepsy & Behavior : E&B
|January 22, 2008
PubMed

Insights

Pentoxifylline (PTX) shows neuroprotective effects against seizures. This study found PTX reduced seizure severity, anxiety, and improved cognitive function in rats, suggesting therapeutic potential for status epilepticus (SE).

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Status epilepticus (SE) is a neurological emergency with significant morbidity.
  • Current treatments for SE have limitations, necessitating novel therapeutic strategies.
  • Oxidative stress and neurochemical imbalances are implicated in SE pathogenesis.

Purpose of the Study:

  • To investigate the neuroprotective potential of pentoxifylline (PTX) against lithium-pilocarpine (Li-Pc)-induced SE in young rats.
  • To evaluate the effects of PTX on seizure parameters, behavior, oxidative stress, and neurochemistry.
  • To assess PTX's impact on hippocampal histology following SE.

Main Methods:

  • Rats were pre-treated with varying doses of PTX (0, 20, 40, 60 mg/kg) before Li-Pc administration to induce SE.
  • Evaluated seizure latency, frequency, and behavioral changes using elevated plus-maze, rotarod, and water maze tests.
  • Assessed oxidative stress markers, hippocampal and striatal dopamine/serotonin levels, and hippocampal histology.

Main Results:

  • PTX significantly reduced SE frequency and severity in a dose-dependent manner.
  • PTX treatment improved motor performance, reduced anxiety, and enhanced learning and memory.
  • PTX attenuated Li-Pc-induced neuronal loss, mossy fiber sprouting, reduced oxidative stress, and normalized dopamine/serotonin levels.

Conclusions:

  • Pentoxifylline exhibits significant neuroprotective effects against Li-Pc-induced SE.
  • PTX demonstrates potential as a prophylactic or therapeutic agent for managing status epilepticus.
  • The findings support further exploration of PTX for SE treatment due to its antioxidant and neurochemical modulatory properties.

More Related Videos

The Pilocarpine Model of Temporal Lobe Epilepsy and EEG Monitoring Using Radiotelemetry System in Mice10:08

The Pilocarpine Model of Temporal Lobe Epilepsy and EEG Monitoring Using Radiotelemetry System in Mice

Published on: February 27, 2018

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...